


08-14-06

AF
90

Express Mail Label No.: ED 855211244 US

Date of Deposit: August 11, 2006



PATENT APPLICATION
Attorney Docket No. 26505-511
(MRC-002)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Ramakrishnan *et al.*
SERIAL NO.: 09/905,212 **GROUP NO.:** 1656
FILING DATE: July 13, 2001 **EXAMINER:** Miguel A. Talavera
TITLE: Crystal Structure of Antibiotics Bound to the 30S Ribosome and Its Use

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE AND AMENDMENT AFTER FINAL REJECTION

Transmitted herewith for filing in the above-reference patent application are the following documents:

Response and Amendment After Final Rejection (5 pages)
Return Receipt Postcard

Applicants believe no fees are due. If the enclosed papers are considered incomplete, the Mail Room is respectfully request to contact the undersigned.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Anthony D. Sabatelli".


Date: August 11, 2006

Anthony D. Sabatelli
Reg. No. 34,714
Rib-X Pharmaceuticals, Inc.
300 George St., Suite 301
New Haven, CT 06511
Tel: 203-848-6920
Fax: 203-624-5627

Express Mail Label No.: ED855211244 US

Date of Deposit: August 11, 2006

Attorney Docket No: 26505-511 (MRC-002)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Ramakrishnan *et al.*
SERIAL NO.: 09/905,212 **GROUP NO.:** 1656
FILING DATE: July 13, 2001 **EXAMINER:** Miguel A. Talavera
TITLE: Crystal Structure of Antibiotics Bound to the 30S Ribosome and Its Use

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE AND AMENDMENT AFTER FINAL REJECTION

Applicant submits this paper in response to the final Office Action of June 28, 2006 for the above-identified patent application. This response is being submitted within the two (2) month statutory deadline of August 28, 2006. Applicant respectfully requests the Examiner to consider the following:

Please amend the above-identified patent application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.